|1.||Newman, R A: 2 articles (08/2001 - 07/2000)|
|2.||Durlacher, Cameron T: 1 article (05/2015)|
|3.||Zhang, Xueji: 1 article (05/2015)|
|4.||Chen, Xiao-Wu: 1 article (05/2015)|
|5.||Zhou, Shu-Feng: 1 article (05/2015)|
|6.||Chow, Kevin: 1 article (05/2015)|
|7.||He, Zhi-Xu: 1 article (05/2015)|
|8.||Yang, Tianxin: 1 article (05/2015)|
|9.||Budd, G Thomas: 1 article (09/2006)|
|10.||Kaur, Hanspreet: 1 article (09/2006)|
09/01/2006 - "The current study reports a phase 1 trial to determine the maximum tolerated dose (MTD) and safety of Anvirzel in patients with advanced, refractory solid tumors. "
09/01/2006 - "Phase 1 trial of Anvirzel in patients with refractory solid tumors."
08/15/2001 - "Anvirzel is an extract of Nerium oleander currently undergoing Phase I clinical evaluation as a potential treatment for cancer. "
07/01/2000 - "Anvirzel, an extract of Nerium oleander, induces cell death in human but not murine cancer cells."
07/01/2000 - "The purpose of this study was to examine the mechanism(s) and differential cell-killing effects of Anvirzel, an extract of oleander (Nerium oleander; family-Apocynaceae), and its derivative compound Oleandrin on human, canine and murine tumor cells. "
|2.||Prostatic Neoplasms (Prostate Cancer)
08/15/2001 - "Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin."
08/15/2001 - "These results demonstrate that Anvirzel, like oleandrin, inhibited FGF-2 export in vitro from PC3 and DU145 prostate cancer cells in a concentration- and time-dependent fashion and may, therefore, contribute to the antitumor activity of this novel treatment for cancer."
|3.||Mouth Neoplasms (Oral Cancer)
|2.||Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)